TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here . During the quarter, the fund returned 11.28% (gross) and 11.02% (net), compared to the Russell 2000 Growth Index by 11.97%. Equities posted double-digit returns in the second quarter as global economic activity measures lifted. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, TimesSquare Capital Small Cap Growth Strategy highlighted stocks such as Vaxcyte, Inc. (NASDAQ: PCVX ). Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company that focuses on developing novel protein vaccines to prevent or treat bacterial infectious diseases. The one-month return of Vaxcyte, Inc. (NASDAQ:PCVX) was 1.10%, and its shares lost 71.50% of their value over the last 52 weeks. On September 11, 2025, Vaxcyte, Inc. (NASDAQ:PCVX) stock closed at $33.06 per share, with a market capitalization of
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (NASDAQ:PCVX) was given a new $77.00 price target on by analysts at Leerink Partners.MarketBeat
- Medicxi Announces €500 Million Fund V [Yahoo! Finance]Yahoo! Finance
- Medicxi closes fifth fund to back ‘asset-centric' startups [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $85.00 price target on the stock.MarketBeat
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- PCVX's page on the SEC website